Q-omics provides the consensus-scored ZNF225 profile across patient tissues and cancer cell-line models. ZNF225 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF225 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF225 RNA expression shows 21,554 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, THCA, and KIRP as cancer lineages where ZNF225 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF225 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF225 survival associations across molecular data types. ZNF225 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF225 RNA expression–survival associations across cancer types. High ZNF225 expression shows unfavorable associations in MESO, LGG and LUSC, but favorable associations in KIRC, HNSC and GBM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF225 RNA expression.
This table summarizes ZNF225 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF225. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF225 shows lower tumor expression in THCA and KICH and higher tumor expression in HNSC, LIHC, BLCA and STAD. The THCA box plot shows higher ZNF225 RNA expression in normal versus tumor tissue (log2 FC = −0.862, t-test p < 0.001).
This table shows molecular features associated with ZNF225 in patient tissues and cancer cell lines. In patient samples, ZNF225 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF225 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
